Market revenue in 2022 | USD 34.7 million |
Market revenue in 2030 | USD 120.0 million |
Growth rate | 16.8% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 67.15% in 2022. Horizon Databook has segmented the Saudi Arabia cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia has become the first Arabian country with more than 10,000 stem cell donors. This indicates the increasing adoption of stem cell therapies in the country. In the gene therapy space, researchers from KAUST, Saudi Arabia, have developed a new delivery system for introduction of gene editing technology into cells.
Such active engagement in this field is expected to increase the demand for cell and gene therapy manufacturing services for precommercial applications in the country. In addition, major companies such as Celltex Therapeutics Corporation are expanding their business in Saudi Arabia.
In March 2019, Celltex Therapeutics Corporation signed a Memorandum of Understanding with Research Products Development Company (RPDC), Saudi Arabia, for commercialization of the company's stem cell technology. Such initiatives are anticipated to propel market growth in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account